Now we are not just an IP company. We have substantial R&D facilities and capabilities. We got about a 24,000 square foot facility in Madison, Wisconsin where our R&D happens. This can also came into the Roche acquisition and what we have there is infrastructure of it that was build by big pharma and that the small biotech would have a very difficult time replicating. And so we have substantial capabilities there.Unidentified Analyst
Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.